13F reference period
Q3 2026
Security Snapshot
Arbutus Biopharma Corp - Common Stock (ABUS) Institutional Ownership
CUSIP: 03879J100
13F Institutional Holders and Ownership History from Q2 2015 to Q3 2026
Institutions Reporting
104
Shares (Excl. Options)
60.53M
Full value: 60,525,779 · shares · 30 Sep 2026Price
$4.78
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ABUS on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 60,525,779
- Total 13F value
- $289,206,904
- Portfolio coverage rank
- 0%
- Share change
- -7,594,453
- Value change
- -$36,480,045
- Number of holders
- 104
- Shares outstanding
- 199,051,833
- SEC-reported price per share
- $4.11
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- ABUS - Arbutus Biopharma Corp - Common Stock is tracked under CUSIP 03879J100.
- 104 institutions reported positions in Q3 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 176 to 104 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$674.86M
Full value: $674,862,301 · USD · 30 Jun 2026.$289.21M
Full value: $289,206,904 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 104 institutions filings for Q3 2026.
Security key
03879J100
13F reference period
Q3 2026
13F holders
104
13D/G owners
5
CIK / CUSIP context first
Open Q3 2026 holders
ABUS full holder history
Arbutus Biopharma Corp SEC filings
Arbutus Biopharma Corp company facts
Arbutus Biopharma Corp insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03879J100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
ABUS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | 20% | -4.8% | $152,986,004 | -$45,913,001 | 29,880,079 | -23% | Roivant Sciences Ltd. | 01 Oct 2026 |
| MORGAN STANLEY | 12% | +38% | $89,303,344 | +$6,191,582 | 18,682,708 | +7.4% | Morgan Stanley | 30 Sep 2026 |
| Two Seas Capital LP | 9.4% | +41% | $79,797,435 | +$25,664,056 | 18,557,543 | +47% | Two Seas Capital LP | 31 Mar 2026 |
| Whitefort Capital Management, LP | 8% | 0% | $73,759,199 | 15,794,261 | 0% | Whitefort Capital Master Fund, LP | 04 Sep 2026 | |
| BlackRock, Inc. | 7.2% | $68,505,679 | 14,331,732 | BlackRock, Inc. | 30 Sep 2026 |
As of 30 Sep 2026,
104
institutional investors reported holding
shares of
Arbutus Biopharma Corp - Common Stock (ABUS).
This represents
30%
of the company’s total
outstanding shares.
60.53M
Full value: 60,525,779 · shares · 30 Sep 2026199.05M
Full value: 199,051,833 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
29%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | 9.2% | 18,376,046 | +3.8% | 0% | $87,837,503 |
| Two Seas Capital LP | 4.1% | 8,143,994 | -57% | 1.6% | $38,928,291 |
| STATE STREET CORP | 3.6% | 7,081,502 | -10% | 0% | $33,849,580 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 6,988,183 | -0.32% | 0% | $33,403,515 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 4,121,119 | +0.08% | 0% | $19,703,115 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.98% | 1,947,718 | +199% | 0% | $9,310,092 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.78% | 1,555,836 | +0.93% | 0% | $7,436,896 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 0.69% | 1,382,857 | +130% | 0.02% | $6,610,058 |
| VANGUARD FIDUCIARY TRUST CO | 0.57% | 1,134,645 | -0.06% | 0% | $5,423,603 |
| OMERS ADMINISTRATION Corp | 0.45% | 894,963 | 0.03% | $4,277,923 | |
| FIRST TRUST ADVISORS LP | 0.35% | 696,258 | 0% | $3,328,113 | |
| Assenagon Asset Management S.A. | 0.31% | 620,717 | 0% | $2,967,027 | |
| Carrera Capital Advisors | 0.29% | 582,144 | +126% | 0.39% | $2,782,648 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.29% | 571,757 | +48% | 0.05% | $2,732,998 |
| BOUSSARD & GAVAUDAN GESTION SAS | 0.28% | 550,000 | 0.48% | $2,695,385 | |
| Quadrature Capital Ltd | 0.24% | 482,074 | +1048% | 0.01% | $2,304,314 |
| Campbell & CO Investment Adviser LLC | 0.2% | 402,141 | +74% | 0.08% | $1,922,234 |
| MARTINGALE ASSET MANAGEMENT L P | 0.15% | 300,424 | +56% | 0.04% | $1,436,027 |
| Swiss National Bank | 0.14% | 286,500 | 0% | 0% | $1,369,470 |
| Ledgewood Wealth Advisors, LLC | 0.14% | 278,436 | 0% | 0.73% | $1,330,924 |
| Verition Fund Management LLC | 0.13% | 252,201 | 0.01% | $1,205,521 | |
| Invesco Ltd. | 0.12% | 245,850 | -2% | 0% | $1,175,163 |
| FRANKLIN TEMPLETON INC | 0.12% | 239,766 | 0% | $973,451 | |
| STRS OHIO | 0.1% | 207,100 | +23% | 0% | $989,938 |
| AMERICAN CENTURY COMPANIES INC | 0.09% | 176,145 | +166% | 0% | $841,973 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
46
Headline period
Q3 2026
Rows shown
1-25 of 46
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 60,525,779 | $289,206,904 | -$36,480,045 | $4.78 | 104 |
| 2026 Q2 | 140,611,167 | $674,862,301 | +$6,561,212 | $4.80 | 176 |
| 2026 Q1 | 138,984,840 | $625,429,886 | +$75,257,846 | $4.50 | 166 |
| 2025 Q4 | 122,028,178 | $586,934,773 | +$19,507,202 | $4.81 | 173 |
| 2025 Q3 | 118,168,575 | $536,370,600 | +$2,487,933 | $4.54 | 166 |
| 2025 Q2 | 118,112,086 | $364,964,865 | +$19,645,984 | $3.09 | 162 |
| 2025 Q1 | 111,778,063 | $390,115,968 | +$29,488,807 | $3.49 | 167 |
| 2024 Q4 | 104,075,822 | $340,339,884 | +$3,767,856 | $3.27 | 153 |
| 2024 Q3 | 101,100,254 | $389,229,670 | +$15,557,626 | $3.85 | 143 |
| 2024 Q2 | 96,687,257 | $298,333,597 | +$40,873,896 | $3.09 | 129 |
| 2024 Q1 | 83,370,717 | $215,132,214 | +$11,550,835 | $2.58 | 118 |
| 2023 Q4 | 78,913,089 | $197,297,266 | +$10,900,831 | $2.50 | 110 |
| 2023 Q3 | 70,841,695 | $143,815,507 | +$8,057,833 | $2.03 | 96 |
| 2023 Q2 | 66,235,432 | $152,407,843 | +$7,387,882 | $2.30 | 109 |
| 2023 Q1 | 62,470,799 | $189,264,221 | +$26,478,755 | $3.03 | 120 |
| 2022 Q4 | 54,227,682 | $126,382,359 | +$17,821,528 | $2.33 | 110 |
| 2022 Q3 | 46,620,587 | $89,144,270 | -$921,936 | $1.91 | 121 |
| 2022 Q2 | 35,268 | $93,574 | -$3,027,847 | $2.18 | 11 |
| 2022 Q1 | 43,886,769 | $130,608,351 | +$4,239,945 | $2.98 | 111 |
| 2021 Q4 | 39,679,851 | $154,349,574 | +$14,066,593 | $3.89 | 114 |
| 2021 Q3 | 34,872,896 | $149,655,492 | +$26,301,612 | $4.29 | 96 |
| 2021 Q2 | 28,908,795 | $87,633,862 | +$7,803,555 | $3.03 | 83 |
| 2021 Q1 | 25,991,001 | $86,467,063 | +$11,894,875 | $3.33 | 88 |
| 2020 Q4 | 21,915,953 | $77,813,914 | -$4,704,362 | $3.55 | 72 |
| 2020 Q3 | 24,142,348 | $75,528,504 | +$7,771,699 | $3.13 | 60 |